Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis

Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients (13 males, 57 females; mean age 49.2 [+ or -] 12.1 years; range 35 to 61 years) and 112 non-RA patients (35 males, 77 females; mean age 42.5 [+ or -] 7.1 years; range 35 to 49 years) were retrospectively and statistically analyzed. Results: In RA patients, positive rates of anti-CCP and RF were 70.0% and 77.1%, respectively. These rates were significantly higher than the rates in non-RA patients (2.7% and 4.5%, respectively; p